How should hypertension be treated in a patient with polycythemia vera?

Treatment of Hypertension in Polycythemia Vera

Treat hypertension in polycythemia vera patients using standard antihypertensive guidelines while simultaneously managing the underlying PV with therapeutic phlebotomy (target hematocrit <45%) and cytoreductive therapy, as the hypertension is often secondary to the myeloproliferative disorder itself and requires addressing both conditions concurrently.

Understanding the Relationship

Hypertension in PV patients represents a complex interplay between the myeloproliferative disorder and cardiovascular risk. The hyperviscosity from elevated hematocrit, thrombocytosis, and leukocytosis directly contributes to elevated blood pressure 1, 2. Importantly, hypertension in PV typically does not respond adequately to antihypertensive therapy alone without controlling the underlying polycythemia 3.

Primary Management: Control the Polycythemia First

Immediate Interventions

• Therapeutic phlebotomy to maintain hematocrit strictly <45% - this is the cornerstone of PV management and directly impacts blood pressure 4
• Low-dose aspirin (81-100 mg daily) unless contraindicated 5, 4

Cytoreductive Therapy Indications

For high-risk patients (age ≥60 years or prior thrombosis) or those with persistent symptoms despite phlebotomy 5:

• Hydroxyurea as first-line cytoreductive agent 6, 4
• Interferon alfa as alternative, particularly in younger patients 6, 5
• Ruxolitinib for patients intolerant or resistant to hydroxyurea 4

The cytoreductive therapy itself often improves blood pressure control by reducing the clonal burden and inflammatory state 2, 7.

Concurrent Antihypertensive Management

Blood Pressure Targets

• Target <130/80 mmHg in most patients 8
• Target <140/80 mmHg in elderly or frail patients 8

First-Line Antihypertensive Agents

For non-Black patients 9, 8:

1. Start with ACE inhibitor or ARB at low dose
2. Add long-acting dihydropyridine calcium channel blocker (e.g., amlodipine)
3. Add thiazide or thiazide-like diuretic if needed

For Black patients 8:

1. Start with ARB plus dihydropyridine CCB or CCB plus thiazide diuretic
2. Increase to full dose
3. Add additional agents as needed

Important Caveats

Avoid beta-blockers as first-line in patients ≥60 years unless compelling indication (e.g., coronary artery disease) 9, 10, 11.

Monitor for renovascular disease - if hypertension remains refractory despite adequate PV control and multiple antihypertensives, consider renal artery stenosis, which can occur concurrently with PV 3.

Manage cardiovascular risk factors aggressively 5:

• Smoking cessation (mandatory)
• Lipid management
• Weight control
• Sodium restriction

Monitoring Strategy

Every 3-6 months 5:

• Blood pressure control
• Hematocrit levels (maintain <45%)
• Complete blood count
• Signs of disease progression
• Thrombotic or bleeding complications

Watch for Red Flags

• Refractory hypertension despite 3+ agents and hematocrit control → investigate for renovascular disease 3
• Extreme thrombocytosis (platelets ≥1000 × 10⁹/L) → increased bleeding risk, may need platelet-lowering therapy 4
• Progressive splenomegaly or symptoms → may indicate need for cytoreductive therapy escalation 5

Clinical Pitfalls to Avoid

1. Do not treat hypertension in isolation - failure to control the underlying PV will result in refractory hypertension 1, 2

2. Do not use ACE inhibitor plus ARB combination - this is contraindicated 9, 10, 12

3. Do not overlook iron deficiency - masked PV with normal hemoglobin due to iron deficiency can delay diagnosis while hypertension and thrombotic complications progress 13

4. Do not delay cytoreductive therapy in high-risk patients - waiting too long increases thrombotic risk despite blood pressure control 4, 14

5. Avoid excessive blood pressure lowering - maintain diastolic BP >60 mmHg, especially in elderly patients or those with coronary disease 15

Algorithm Summary

1. Confirm PV diagnosis (JAK2 mutation, bone marrow if needed)
2. Initiate phlebotomy immediately (target hematocrit <45%)
3. Start low-dose aspirin (unless contraindicated)
4. Begin antihypertensive therapy per standard guidelines (ACE-I/ARB + CCB ± diuretic)
5. Add cytoreductive therapy if high-risk or symptomatic (hydroxyurea first-line)
6. Monitor response every 3-6 months
7. Investigate for secondary causes if hypertension remains refractory despite adequate PV control

The key principle is that hypertension in PV requires dual management: treating both the elevated blood pressure with standard antihypertensives AND the underlying myeloproliferative disorder with phlebotomy and cytoreductive therapy 2, 4.